Study of return of kidney disease after transplant
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This observational study looks at people with FSGS or minimal change disease whose kidney disease came back after a transplant. The goal is to better understand patterns of recurrence and what factors may be linked to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a kidney transplant at any time from 2000 onward.
- Before the transplant, you were diagnosed with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
- Your diagnosis in the native (original) kidney was not any other kidney disease.
- Your FSGS or MCD was not caused by another known condition (for example lupus, IgA nephropathy, or cancer).
- This is a retrospective (past-data) study, meaning it uses existing medical records rather than asking for new consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a registry that collects medical information from people with nephrotic syndrome caused by FSGS or minimal change disease (MCD). It may help doctors better understand these conditions and improve future care, especially by tracking patients over time.
This study tests three experimental drugs (frexalimab, brivekimig, and rilzabrutinib) for people ages 16 to 75 with a type of kidney disease called primary FSGS or minimal change disease. The goal is to see if these drugs can reduce protein in your urine and help protect your kidneys.
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
This study follows people who are getting a kidney transplant (first or later) to better understand how the body recovers, using health tracking and “gene/protein” (proteogenomic) information. It may help doctors predict complications and improve care after transplant.
This trial is testing a new treatment approach for people with certain kidney diseases called podocytopathies (like FSGS and MCD). It may help if you have active disease, even after a kidney transplant, or if you have another type of kidney inflammation.
This study looks at tissue samples from kidney transplant patients who have a specific type of long-term rejection called chronic active humoral rejection (cAMR). It aims to better understand the condition and help future patients.
Hear when a new Focal Segmental Glomerulosclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.